All In Biotech

Drug Trial Radar · NCT07679113

IPG1094 Phase I Study for China Healthy Participants

A Phase I Clinical Trial Evaluating Pharmacokinetic Characteristics of IPG 1094 in Chinese Healthy Adults

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jan 30, 2027

Study completion Jan 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Xuhui Central Hospital, Shanghai
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 open-label study enrolls 24 healthy Chinese adults to investigate the pharmacokinetics, safety and tolerability of oral IPG1094 tablets. The trial includes two parts. Part A (12 participants) uses a crossover design to explore the impact of food on a single 200 mg dose of IPG1094; participants will receive the drug under fasting and post-meal conditions on separate days, with intensive blood sampling for PK analysis. Part B (12 participants) evaluates multiple-dose PK, where participants take 200 mg IPG1094 twice daily for 10 days to observe drug exposure and accumulation. All participants will undergo comprehensive safety checks such as lab tests, ECG and adverse event monitoring during screening, treatment and post-dosing follow-up. No placebo or blinding is applied in this study.

Conditions

  • Healthy Volunteers

Interventions

  • IPG1094 TabletsDrug

    Part A:Oral administration with 240 mL water; fasted: ≥10h overnight fast, no water 1h before/after dosing; fed: take drug within 30 mins of finishing standardized high-fat breakfast. Single dose 200 mg per cycle, two cycles separated by 5-day washout. Part B:Oral 200 mg twice daily, morning \& evening, continuous 10 days; each dose taken with 240 mL water, restricted water intake 1h pre/post dose; steady-state PK sampling for accumulation assessment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A:Time to maximum concentration (Tmax)Time frame: Full PK sampling profiles on Day 1 and Day 6
  2. Part A:Plasma maximum concentration (Cmax)Time frame: Full PK sampling profiles on Day 1 and Day 6
  3. Part A:Terminal elimination half-life (t1/2)Time frame: Serial blood samples collected up to 96 hours post-dose on Day 1 and Day 6
  4. Part B:Steady-state maximum plasma concentration (Css,max)Time frame: Full PK sampling profiles on Day 10
  5. Part B:Time to steady-state maximum concentration (Tss,max)Time frame: Full PK sampling profiles on Day 10
  6. Part B:Steady-state terminal elimination half-life (t1/2)Time frame: Serial blood samples collected up to 72 hours post-dose on Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, Xuhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.